61

ŝ

Phospho-PDGF Receptor β (Tyr751) Antibody



Orders:	877-616-CELL (2355 orders@cellsignal.com
Support:	877-678-TECH (8324
Web:	info@cellsignal.com cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

For Research Use Only. Not for Use in Diagnostic Procedures.

Applications: W, FC-FP	Reactivity: H M R	Sensitivity: Endogenous	MW (kDa): 190	Source/Isotype: Rabbit	UniProt ID: #P09619	Entrez-Gene Id: 5159	
Product Usage Information		Application Western Blotting Flow Cytometry (Fixed	d/Permeabilized)			Dilution 1:1000 1:200	
Storage		Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 μg/ml BSA and 50% glycerol. Store at 20°C. Do not aliquot the antibody.			ycerol. Store at –		
Specificity/Sen	sitivity	Phospho-PDGF Receptor β (Tyr751) Antibody detects PDGF receptor β only when phosphorylated Tyr751. The antibody may cross-react with PDGF receptor α when highly overexpressed.			osphorylated at sed.		
Source / Purification		Polyclonal antibodies are produced by immunizing animals with a synthetic phosphopeptide corresponding to residues surrounding Tyr751 of human PDGF receptor β. Antibodies are purified by protein A and peptide affinity chromatography.					
Background		Platelet derived grown isoforms (PDGF AA, Pl closely related recepto PDGFRa and PDGFRβ domains, while the kin homology (1). PDGFRa homodimers bind PD PDGF receptor a/β bin PDGFRa and PDGFRβ Various cells differ in which may account fo induces receptor dime cytoplasmic SH2 dom PLCy, and NCK. A num lead to control of cell kinase-insert region of derived from Tyr751 of terminal SH2 domain PDGFRβ-mediated PI3	th factor (PDGF) fam DGF AB, PDGF BB, Pl or tyrosine kinases, share 75% to 85% so nase insert and carb α homodimers bind GF BB and DD isofor nds PDGF B, C, and I can each form hete the total number of or responsive differe erization and autopl ain-containing signa ber of different sign growth, actin reorga of PDGFRβ is the doc of PDGFRβ is the doc of the p85 subunit of 8 kinase activation (8	ily proteins exist as seve DGF CC, and PDGF DD) t PDGF receptor α (PDGF equence homology betw oxy-terminal tail region all PDGF isoforms excep ms, as well as the PDGF D homodimers, as well a rodimers with EGFR, wh receptors present and i nces among cell types to hosphorylation, followed al transduction molecule haling pathways are init anization, migration, and king site for PI3 kinase (Val-Pro-Met-Leu) inhibit of PI3 kinase with PDGFf 8).	eral disulphide-bon that bind in a specif Ra) and PDGF recep ween their two intra s display a lower lev of those containing - AB heterodimer. Ti s the PDGF AB hete ich is also activated n the receptor subu o PDGF binding (4). d by binding and ac es, such as GRB2, Sr iated by activated P d differentiation (5). (6). Phosphorylated the association of RB (7). Tyr740 is also	ded, dimeric ic pattern to two itor β (PDGFR β). icellular kinase vel (27% to 28%) of PDGF D. PDGFR β he heteromeric rodimer (2). I by PDGF (3). init composition, Ligand binding tivation of c, GAP, PI3 kinase, 'DGF receptors and . Tyr751 in the pentapeptides the carboxy- o required for	
Background Re	ferences	1. Deuel, T.F. et al. (19 2. Bergsten, E. et al. (2 3. Betsholtz, C. et al. (2 4. Coughlin, S.R. et al. 5. Ostman, A. and Hel 6. Panayotou, G. et al. 7. Ramalingam, K. et a 8. Kashishian, A. et al.	88) <i>Biofactors</i> 1, 213 2001) <i>Nat. Cell Biol.</i> 3 2001) <i>Bioessays</i> 23, - (1988) <i>Prog. Clin. Bi</i> din, C.H. (2001) <i>Adv.</i> (1992) <i>EMBO J.</i> 11, - al. (1995) <i>Bioorg. Me</i> (1992) <i>EMBO J.</i> 11, -	3-217. 3, 512-516. 494-507. <i>iol. Res.</i> 266, 39-45. <i>Cancer Res.</i> 80, 1-38. 4261-4272. <i>id. Chem.</i> 3, 1263-1272. 1373-1382.			
Species Reactiv	vity	Species reactivity is de	etermined by testing	յ in at least one approve	ed application (e.g.,	western blot).	
Western Blot B	uffer	IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.					
Applications Ke	ey	W: Western Blotting F	C-FP: Flow Cytomet	ry (Fixed/Permeabilized))		
Cross-Reactivit	у Кеу	H: Human M: Mouse	R: Rat				

Trademarks and Patents	Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.			
	All other trademarks are the property of their respective owners. Visit cellsignal.com/trademarks for more information.			
Limited Uses	Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.			
	Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.			